HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    

Zacks Mutual Fund Rank
Did you know that Zacks now ranks mutual funds? We've reinvented the way mutual funds are rated.   Try it now.
Quote:
Login Free Membership
Search:

 
Analyst Blog  

MDT Launches New Bone Grafter

By: Zacks Equity Research
November 12, 2009 | Comments: 0
Recommended this article (1)
MDT | STJ | BSX
Print    Share

Medtronic, Inc. (MDT - Analyst Report) recently launched MASTERGRAFT Strip - a new, highly flexible ceramic scaffold used in combination with a patient’s own bone for fusing multiple levels of the posterolateral spine, in the U.S. The strip is used by surgeons for a variety of bone grafting procedures.
 
MASTERGRAFT Strip is primarily used when the spine loses stability or its natural shape. The product offers a continuous latticework for longer grafting procedures at the back of the spine. It also enables maximization of the bony surface area contact and allows for continuous bone growth over large bony gaps. MASTERGRAFT Strip is available in unique lengths that eliminate the requirement of multiple strip units for a long fusion.
 
MASTERGRAFT Strip’s unique features and ease of handling during implantation makes it a preferred choice for spine surgeons. We therefore expect the product to increase the Spinal and Biologics business of Medtronic.

Medtronic is one of the world’s leading medical technology companies, specializing in implantable and interventional therapy devices and products. The company’s main competitors include St. Jude Medical (STJ - Analyst Report) and Boston Scientific Corp. (BSX - Analyst Report).

Medtronic’s management has a typical ‘ONE Medtronic’ approach that encompasses the following goals: drive sustainable long-term growth of 9%-11% through innovation; focus on operating margins -- increase by 300 to 400 basis points; EPS growth of 11%-14% and return a minimum of 40%-50% of free cash flow to shareholders annually; and align the organization for consistent execution. Medtronic’s fiscal first quarter results indicate that the company is well on track in achieving these goals.


Email

Print

Share

RSS

Rate Pos

Rate Neg

Comment
Free Stock Analysis From Zacks
  Includes Zacks Long-Term Recommendation and Target Price
Read/Post Comments (0) | Recommended this article (1)
 Posting Comment...
There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]
Comments (Limit 1000 Characters - Used: 0)
Display Name: Email Address:  
 Loading Comments...
Be the first to comment on this article!
Best Stocks. Best Insight. Join Now...it's FREE!
Over 550,000 investors look forward to the timely insights in our email newsletter; Zacks Profit from the Pros. In each daily issue you will find:
  • Free  Four Zacks #1 Rank "Strong Buy" Stocks
  • Free  Timely Market Commentary
  • Free  Wealth Management Tips
  • Free  Profitable Strategy Screens
  • Free  Bull and Bear Stocks of the Day
Zacks FREE Registration

More Zacks Resources

Market Summary Feb 10, 2010 02:24 am ET
DJIA 10058.64  150.25 1.52%
NASD 2150.87  0.00 0.00%
S&P 500 1070.52  13.78 1.30%